INCY
Incyte Corporation
Biotechnology · Healthcare · United States
120.52
close · 2026-08-13
value
73
cheaper than peers73
quality
95
stronger fundamentals95
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.74× | 82 |
| EV to EBITDA | 12.77× | 64 |
| forward P/E | 13.57× | 64 |
| price to book | 3.82× | 61 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.7% | 94 |
| operating margin | 25.6% | 87 |
| return on equity | 30.8% | 86 |
| revenue growth | 20.9% | 44 |
4 of 4 measures available
Facts
| market cap | $24B |
| free cash flow | $558.9M |
| employees | 2,844 |
| first trade | 1993-11-04 |
| next earnings | 2026-07-28 |
| fundamentals updated | 2026-07-29 |